Medpacto Stock Total Asset
| 235980 Stock | KRW 3,515 80.00 2.23% |
MedPacto fundamentals help investors to digest information that contributes to MedPacto's financial success or failures. It also enables traders to predict the movement of MedPacto Stock. The fundamental analysis module provides a way to measure MedPacto's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MedPacto stock.
MedPacto |
MedPacto Company Total Asset Analysis
MedPacto's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current MedPacto Total Asset | 133.35 B |
Most of MedPacto's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedPacto is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, MedPacto has a Total Asset of 133.35 B. This is much higher than that of the sector and significantly higher than that of the Biotechnology industry. The total asset for all Republic of Korea stocks is notably lower than that of the firm.
Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
MedPacto Fundamentals
| Return On Equity | -58.54 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 1.18 T | |||
| Shares Owned By Insiders | 33.90 % | |||
| Shares Owned By Institutions | 5.45 % | |||
| Gross Profit | (1.66 M) | |||
| EBITDA | (26.36 B) | |||
| Net Income | (17.04 B) | |||
| Cash And Equivalents | 1.29 B | |||
| Total Debt | 75.41 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 19.90 X | |||
| Cash Flow From Operations | (25.15 B) | |||
| Target Price | 26000.0 | |||
| Market Capitalization | 440.59 B | |||
| Total Asset | 133.35 B | |||
| Z Score | 3.0 | |||
| Net Asset | 133.35 B |
About MedPacto Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedPacto's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedPacto using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedPacto based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in MedPacto Stock
MedPacto financial ratios help investors to determine whether MedPacto Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedPacto with respect to the benefits of owning MedPacto security.